DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Firms / W••••••• B••••••••• L••
W••••••• B••••••••• L••
W••••••• BioPartners is a people-first life science venture capital firm that crafts companies around world-class entrepreneurs. Immersed in the Los Angeles biotech community, we incubate the most promising companies to turn breakthroughs into treatments for patients in need.
both early and growth/opportunity families, reported GAV $1,487M
Importance
43
elevated
Active deployment
55
elevated
Emerging
0
low
Completeness
81
high
Freshness
98
high
Research priority
18
moderate
Identity and regulatory footprint
- Headquarters
- W••••••• Village, CAadviserinfo.sec.gov
- Office address
- 3075 TOWNSGATE ROAD, SUITE 140, W••••••• Village, CA, 91361adviserinfo.sec.gov
- Business phone
- (805) 465-9588adviserinfo.sec.gov
- Website
- w•••••••••.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 30, 2026
- Private funds reported
- 4 (4 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $1.4Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business phone
- (805) 465-9588adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
12 observed deals
Stated (the firm’s website)
- Sectors
- biotech
- Stages
- series a
- Geography
- los angeles
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation
series a 100%
Stage at first entry
series a 100%
Sectors
unknown 58%Biotechnology 33%Other 8%
lead rate 100%follow-on rate 0%new logos, 12 months 9
Funds and vehicles
4 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| W••••••• B••••••••• F••• I••• L••• | Fund | 2024 adv first reported | Early deployment | $456M Dec 13, 2024 | 37 | $0 of $450M | Jun 29, 2023 |
| W••••••• B••••••••• F••• I•• L••• | Fund | 2021 adv first reported | Mature | $405M Dec 13, 2024 | 50 | $0 of $450M | Jul 6, 2020 |
| W••••••• B••••••••• O••••••••• F••• I• L••• | Opportunity fund | 2020 form d first sale | Mature | $103M Dec 13, 2024 | 25 | $100M of $100M | Jun 14, 2021 |
| W••••••• B••••••••• F••• I• L••• | Fund | 2018 form d first sale | Harvest | $523M Dec 13, 2024 | 35 | $320M of $320M | Sep 4, 2018 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
20 current, 4 departed
L••••• P••••
AssociateAssociate
C•••• M•
Operating partnerOperating Partner
B••• S•••••••••
PartnerManaging Director · since Mar 1, 2018
B••• S•••••••••
PartnerFounding Managing Director
B••• S•••••••••
PartnerManaging Director · since Mar 1, 2018
C•••• M•
PartnerFounding Managing Director
D•••• A••••••
PartnerManaging Director
D•••• D• A••••••
PartnerManaging Director · since Mar 1, 2023
D•••• D• A••••••
PartnerManaging Director · since Mar 1, 2023
M••• C•••••••••
PartnerManaging Director · since Jan 1, 2022
M••• C•••••••••
PartnerManaging Director · since Jan 1, 2022
M••• C•••••••••
PartnerManaging Director
A•••••• A••••••
Platform and operationsFinance Manager
B••••• P•••••••
Platform and operationsVice President Finance And Operations · since Aug 1, 2021
B••••• P•••••••
Platform and operationsVice President Finance And Operations · since Aug 1, 2021
B••••• P•••••••
Platform and operationsVP Finance & Operations
J••••••• K••••••
Platform and operationsGeneral Counsel · since Jan 1, 2022
J••••••• K••••••
Platform and operationsGeneral Counsel
J••••••• K••••••
Platform and operationsGeneral Counsel · since Jan 1, 2022
K•••• M••••••••
PrincipalDirector of Administration
4 departed (kept with end dates)
- S••• H••••• · Managing Director · Jan 1, 2019 to Mar 30, 2026 Fact
- J••••••• K•••••• · General Counsel · ? to Sep 16, 2026 Inference
- P•••• M•••••• C••••••• · Chief Operating Officer · Feb 1, 2021 to Aug 17, 2023 Inference
- S•••• A•••• R•••• · Chief Operating Officer · Mar 1, 2018 to Mar 31, 2021 Inference
Investments on record
12 edges, 12 companies, 3 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
7 relationships from shared deals, counted for the whole firm
NEW Leaf Venture Partners 2 shared · recurringOmega Fund Management, LLC 1 shared · one timeCRV, LLC 1 shared · one timeAsset Management Ventures, LLC 1 shared · one timeForesite Capital 1 shared · one timeArch Venture Partners 1 shared · one timeVersant Venture Management, LLC 1 shared · one time · they led 1 · we led 1
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
18 dated events
- Sep 16, 2026J••••••• K•••••• (General Counsel) no longer on the team page of W••••••• B••••••••• L••Person leftPeopleInferenceJ••••••• K••••••Venture organization websites (about, team, portfolio, thesis, news pages)
- Mar 30, 2026S••• H••••• (Managing Director) no longer on Schedule A of W••••••• B••••••••• L••Person leftPeopleInferenceS••• H•••••IAPD Form ADV Part 1 PDF per firm (current filing, Schedule D 7.B.(1) and Schedule A)
- Dec 12, 2024S••• H••••• (Managing Director) no longer on Schedule A of W••••••• B••••••••• L••
- Dec 12, 2024B••• S••••••••• (Managing Director) no longer on Schedule A of W••••••• B••••••••• L••
- Mar 30, 2024W••••••• B••••••••• F••• I••• L••• first reported on Form ADV by W••••••• B••••••••• L•• (Venture Capital Fund), GAV $456,012,344Fund first reported on Form ADVFundsFactW••••••• B••••••••• F••• I••• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Aug 17, 2023P•••• M•••••• C••••••• (Chief Operating Officer) no longer on Schedule A of W••••••• B••••••••• L••
- Mar 1, 2023D•••• D• A•••••• joined Schedule A of W••••••• B••••••••• L•• as Managing Director
- Jan 1, 2022J••••••• K•••••• joined Schedule A of W••••••• B••••••••• L•• as General Counsel
- Jan 1, 2022M••• C••••••••• joined Schedule A of W••••••• B••••••••• L•• as Managing Director
- Aug 1, 2021B••••• P••••••• joined Schedule A of W••••••• B••••••••• L•• as Director Of Finance
- Mar 31, 2021W••••••• B••••••••• F••• I•• L••• first reported on Form ADV by W••••••• B••••••••• L•• (Venture Capital Fund), GAV $429,036,729Fund first reported on Form ADVFundsFactW••••••• B••••••••• F••• I•• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 31, 2021W••••••• B••••••••• O••••••••• F••• I• L••• first reported on Form ADV by W••••••• B••••••••• L•• (Venture Capital Fund), GAV $67,905,659Fund first reported on Form ADVFundsFactW••••••• B••••••••• O••••••••• F••• I• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 31, 2021S•••• A•••• R•••• (Chief Operating Officer) no longer on Schedule A of W••••••• B••••••••• L••
- Feb 1, 2021P•••• M•••••• C••••••• joined Schedule A of W••••••• B••••••••• L•• as Chief Operating Officer
- Jan 1, 2019S••• H••••• joined Schedule A of W••••••• B••••••••• L•• as Managing Director
- Oct 24, 2018W••••••• B••••••••• L•• first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Oct 24, 2018W••••••• B••••••••• F••• I• L••• first reported on Form ADV by W••••••• B••••••••• L•• (Venture Capital Fund), GAV $326,530,612Fund first reported on Form ADVFundsFactW••••••• B••••••••• F••• I• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 1, 2018B••• S••••••••• joined Schedule A of W••••••• B••••••••• L•• as Managing Director
Classification history
- Sep 12, 2026Multi-stage venture firm (confirmed, 95%, cls-1)both early and growth/opportunity families, reported GAV $1,487M
Evidence
55 observations from 4 sources